OBJECTIVE To describe the incidence and clinical relevance of biochemical and objective responses to abiraterone acetate (AA) withdrawal (AAWD) in patients with castration-resistant prostate cancer (CRPC). MATERIALS AND METHODS Twenty-six patients with progressive CRPC treated with first-line docetaxel-based chemotherapy were administered with AA at the standard dose of 1000 mg/day in combina...

Abiraterone acetate (AA), after metabolization to abiraterone, is an oral inhibitor of the cytochrome P450C17 (CYP17) complex. It inhibits the production of androgens by interfering with the enzymes C17a hydroxylase and C17-C20 lyase. It was tested in patients with metastatic castration-resistant prostate cancer and showed promising results in Phase I and II studies with prostate specific antig...

1 CCR Perspectives in Drug Approval Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary Paul G. Kluetz, Yang-Min Ning, V. Ellen Maher, Lijun Zhang, Shenghui Tang, Debasis Ghosh, Robeena Aziz, Todd Palmby, Elimika Pfuma, Jeanne Fourie Zirkelbach, Nitin Mehrot...

As part of an EU-supported IMIPREDECT consortium, a Dutch study showed that abiraterone acetate (AA) may have an additional mechanism of action to block growth of castration resistant prostate cancer (CRPC). The study, which won the first prize for best oncology abstract at the 28th European Association of Urology (EAU) Congress, showed that antiandrogenic properties of AA may stop androgen rec...

ObjectivesAbiraterone acetate is registered for the treatment of metastatic castration-sensitive and resistant prostate cancer (mCRPC). Treatment outcome associated with plasma trough concentrations (Cmin) abiraterone. Patients a Cmin below target 8.4 ng/mL may benefit from optimization by dose increase or concomitant intake food. This study aims to investigate cost-effectiveness monitoring abi...

T herapies targeting the androgen receptor (AR) axis have constituted the Holy Grail in the management of advanced prostate cancer for seven decades. These hormonal therapies have traditionally taken two main forms: those that suppress gonadal androgen synthesis (e.g., the gonadotropin releasing hormone agonists/antagonists, such as leuprolide), and those that inhibit the AR directly (e.g., the...

OBJECTIVE To review the activity of 3 new agents approved for the management of advanced castration-resistant prostate cancer (CRPC): sipuleucel-T, cabazitaxel, and abiraterone acetate. DATA SOURCES Literature was accessed through MEDLINE (1977-June 2012) and abstracts from the American Society of Clinical Oncology (2000-2012) using the terms castration-resistant and hormone-refractory prosta...

Recent breakthrough therapies targeting androgen receptor signalling in castration resistant prostate cancer (CRPC) involve multifunctional androgen receptor (AR) blockade and exhaustive androgen deprivation. Nevertheless, limitations to an enduring effectiveness of new drugs are anticipated in resistance mechanisms occurring under such treatments. In this study we used CRPC cell models VCaP an...

Abiraterone acetate (AA) 1000-mg daily, a selective irreversible androgen biosynthesis inhibitor of cytochrome P450 c17 (CYP17) enzyme, is used in combination with prednisone 10-mg daily to treat docetaxel-treated patients with metastatic castration-resistant prostate cancer (mCRPC). Several studies have demonstrated the safety and efficacy of this compound in men with mCRPC. Interim results fr...